drugset / Trial / NCT02257294

A Trial of Low-dose Adjunctive alTeplase During prIMary PCI

NCT02257294

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine the safety and efficacy of reduced doses (10 mg and 20 mg) of intra-coronary alteplase compared with placebo as an adjunct to PCI in reducing MVO and its consequences in high risk patients with STEMI.

Timeline

Start
2016-03
Primary completion
2018-07
Completion
2019-05-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Alteplase Protein / enzyme biologic 10 mg Other
Comparator Alteplase Protein / enzyme biologic 20 mg Other

Indications